Vistagen Therapeutics, Inc.

VTGN

$81M

Micro Cap

NASDAQPharmaceutical Preparations🇺🇸North AmericaSOUTH SAN FRANCISCO59 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Apr 15, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

2 upcoming, 0 past

Phase 2Next

Fasedienol Nasal Spray - Fasedienol Nasal Spray Phase 2 Results Expected

April 2026~Fasedienol Nasal Spray - Fasedienol Nasal Spray60

Primary completion for Fasedienol Nasal Spray - Fasedienol Nasal Spray trial (NCT06809179) in Social Anxiety Disorder

Source

⭐Phase 3

Fasedienol Nasal Spray Phase 3 Results Expected

April 2026~Fasedienol Nasal Spray236

Primary completion for Fasedienol Nasal Spray trial (NCT06615557) in Social Anxiety Disorder (SAD)

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

PH94B Nasal Spray

Phase 3

Social Anxiety Disorder

Fasedienol Nasal Spray

Phase 3

Social Anxiety Disorder (SAD)

AV-101

Phase 2

Major Depressive Disorder

PH94B

Phase 2

Adjustment Disorder With Anxious Mood

Fasedienol Nasal Spray - Fasedienol Nasal Spray

Phase 2

Social Anxiety Disorder

Drug Name	Phase	Indication	Designations
PH94B Nasal Spray	Phase 3	Social Anxiety Disorder	-
Fasedienol Nasal Spray	Phase 3	Social Anxiety Disorder (SAD)	-
AV-101	Phase 2	Major Depressive Disorder	-
PH94B	Phase 2	Adjustment Disorder With Anxious Mood	-
Fasedienol Nasal Spray - Fasedienol Nasal Spray	Phase 2	Social Anxiety Disorder	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

VTGN News